Other
B-Cell NHL
0
Pipeline Programs↗
2
Active Trials↗
6
Companies Involved↗
B-cell NHL is an early-stage landscape with 0 programs across 6 companies. The most active players are Alopexx Oncology, LLC, Johnson & Johnson, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
10
clinical trials
Completed4 · 40%
Terminated2 · 20%
Recruiting2 · 20%
Unknown status1 · 10%
Withdrawn1 · 10%
Clinical Trials
Trial Activity
10 trials
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL
Completed·—·Phase 1·NCT00709033·3 enrolled
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
Completed·—·Phase 2·NCT00577278·41 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)